Dr. Richard Cheng and Dr. C. Michael Gibson discuss: Presentation, screening, and disease progression of variant ATTR-CM
Disclosures: Sponsored by BridgeBio Pharma, Inc
Clinical Trial Results
Search
Dr. James Ampadu and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. Richard Wright and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc
Dr. Joshua Mitchell and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. M. Trejeeve Martyn and Dr. C. Michael Gibson discuss: The importance of early screening, diagnosis, and treatment for ATTR-CM
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. Adam Castano and Dr. C. Michael Gibson discuss: ACT-EARLY, a Phase 3 Study – Clinical Trial Results
Disclosures: Sponsored by BridgeBio Pharma, Inc
THIS WEEK IN OBESITY
Participants randomized to the placebo arm in obesity trials often do not lose weight and as a result may drop out […]
THIS WEEK IN OBESITY
Dr. Javed Butler and Dr. C. Michael Gibson discuss the flaws of BMI in obesity trials